One intervention, every measured benefit and result that did not improve. See who it moved for, where it stayed neutral or went the other way, and the next hypothesis Phoenix can validate.
Phoenix APOE4 Research · Reviewed by Kevin Tran, APOE4/4 carrier and founder · Data through 2026-08-23 · How to read this research
How to read this
Observational research: real APOE4 carriers tracked over time, each compared with their own earlier self. Members chose their interventions, with no randomisation or placebo group. Everything else they changed is shown beside each result.
Read the full methods and limitsPhoenix has measured Metformin against 4 exact outcomes for APOE4 carriers. Member #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days. Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. Member #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days. Member #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days.
| Outcome | Direction | What we observed |
|---|---|---|
| Glucose | Positive individual result | Member #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days. |
| Insulin | Positive individual result | Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. |
| LDL cholesterol | Positive individual result | Member #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days. |
| Triglycerides | Positive individual result | Member #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days. |
Phoenix has measured Metformin against 4 exact outcomes for APOE4 carriers. Member #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days. Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. Member #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days. Member #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days.
Member #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.
Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.
Member #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.
Member #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days. Support: 1 logged members, 1 members with repeats, 1 observations, 2 measurements.
Search by health goal or intervention to see what changed for real members, including results that moved the wrong way.
Metformin · 4 outcomes shown.
Glucose: Decrease 26 mg/dL
Cases: 1
Member #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days.
Metformin
✓Positive individual resultMember #2351C3's Glucose moved from 114 to 88 mg/dL in 718 days.
Glucose
Before114After88mg/dL-22.8%
718 days between measurements
What else changed: no nearby starts were recorded.
Next study: repeat Glucose after a dated Metformin window.
Insulin: Decrease 6.1 uIU/mL
Cases: 1
Member #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated.
Metformin
✓Positive individual resultMember #15000A lowered fasting insulin from 12.6 to 6.5 uIU/mL in 162 days on metformin and tirzepatide, both undated.
Insulin
Before12.6After6.5uIU/mL-48.4%
162 days between measurements
Full stack credited: Metformin (lead), Tirzepatide (undated).
What else changed: no nearby starts were recorded.
Next study: repeat Insulin after a dated Metformin window.
LDL cholesterol: Decrease 24 mg/dL
Cases: 1
Member #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days.
Metformin
✓Positive individual resultMember #2351C3's LDL cholesterol moved from 83 to 59 mg/dL in 881 days.
LDL cholesterol
Before83After59mg/dL-28.9%
881 days between measurements
Full stack credited: Metformin (lead), Niacin (co), Rosuvastatin (co), Ezetimibe (undated).
What else changed: no nearby starts were recorded.
Next study: repeat LDL cholesterol after a dated Metformin window.
Triglycerides: Decrease 39 mg/dL
Cases: 1
Member #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days.
Metformin
✓Positive individual resultMember #2351C3's Triglycerides moved from 101 to 62 mg/dL in 795 days.
Triglycerides
Before101After62mg/dL-38.6%
795 days between measurements
Full stack credited: Metformin (lead), Omega-3 (co), Rosuvastatin (co), Ezetimibe (undated).
What else changed: no nearby starts were recorded.
Next study: repeat Triglycerides after a dated Metformin window.
The 43-page study: what members tried, how their bloodwork and wearable results changed, and what else changed alongside them.
Turn evidence into your next test
476 members have already tried, measured and logged. Join Phoenix and your next blood draw joins the same Navigator you are reading.
Full research index
Choose an outcome, like LDL cholesterol or sleep, or an intervention, like training: both paths open the same measured records.